Skip to main content

Healthspan Principles

How Value Is Created​

The healthspan industry creates value by shifting the care model from episodic to continuous — replacing "treat disease after onset" with "maintain and extend vitality before onset." Every dollar of value traces to one of three levers: extending the years a person functions at high capacity, compressing the period of decline into a shorter window at life's end, or lowering the cost of achieving both.

That is structurally different from sick-care, which creates value by resolving a crisis. Sick-care has a natural ceiling — the patient is healthy or they're not. Healthspan has no ceiling. A 40-year-old optimising their HRV, sleep quality, and inflammatory markers is a customer for life, with expanding willingness to pay as the data compounds.

Essential Data​

The four data types whose absence breaks the healthspan value chain:

Continuous biomarker streams — heart rate variability, SpO2, sleep architecture, glucose trends, activity load. Without them, everything reverts to episodic guesswork. Decisions driven: protocol adjustment, overtraining detection, recovery scheduling.

Longitudinal health history — genomics, lab panels, prior diagnoses, medication history. The pattern only emerges over years. A single data point is noise; a decade is signal. Decisions driven: risk stratification, personalised protocol design, early anomaly detection.

Behavioural compliance signals — did the person follow the protocol? Adherence data is the feedback loop that separates a recommendation engine from a health-change engine. Without it, the system can optimise the protocol but not the person. Decisions driven: intervention timing, coaching escalation, protocol simplification.

Outcome data — did health markers improve? This is the hardest data to collect (requires long time horizons) and the most valuable (proves the protocol works). Without outcome data, the industry cannot distinguish effective interventions from expensive placebos. Decisions driven: protocol validation, product iteration, clinical evidence building.

Nomenclature​

Healthspan — the years a person lives in good health, free from chronic disease and significant functional decline. Distinct from lifespan (total years alive). A 95-year-old with dementia has long lifespan; short healthspan.

Longevity — the pursuit of extending both lifespan and healthspan simultaneously. In research contexts, longevity often refers specifically to the biology of ageing. In market contexts, it spans supplements, diagnostics, and lifestyle interventions.

Sick-care — the incumbent model: reactive, episodic, provider-controlled healthcare delivered in response to disease onset. The term is descriptive, not pejorative — the model works for acute conditions. The gap: 70–80% of healthcare costs arise from conditions that are preventable [CDC / Milken Institute 2023].

Morbidity compression — the goal of shifting the period of serious illness and decline to as late in life as possible and as short as possible. The ideal: live well until 90, decline briefly, die without a decade of managed deterioration.

Biomarker — a measurable biological indicator (blood panel, HRV, inflammatory marker, telomere length) that tracks health state over time. Biomarkers are the data layer that makes continuous health monitoring possible.

Protocol — a structured set of lifestyle, nutritional, and supplementation interventions targeting a specific health outcome. Protocols replace one-size-fits-all advice with personalised, evidence-graded recommendations.

DeSci — Decentralised Science. Research funding and data governance models that use blockchain-based coordination to pool patient data with patient consent, enabling research at scale without surrendering data sovereignty to a central institution.

Decisions Data Drives​

Protocol adjustment — driven by continuous biomarker streams. Quality: moderate today (device accuracy improving but consumer-grade sensors carry noise). Impact of bad data: over- or under-training recommendations; supplement timing errors.

Risk stratification — driven by longitudinal history + genomics. Quality: low (genomics accessible, but integration across data types is fragmented). Impact: failing to identify individuals at elevated risk early enough for preventive intervention.

Compliance intervention — driven by behavioural signals. Quality: very low (most apps lack passive compliance monitoring; relies on self-report). Impact: the single biggest reason digital health fails — the system doesn't know the person stopped following the protocol.

Outcome attribution — driven by long-horizon outcome data. Quality: near-absent at population scale for consumer healthspan. Impact: inability to distinguish effective products from expensive noise; no defensible evidence base for pricing.

Technology Lens​

AI — the protocol personalisation engine. Pattern detection across biomarker streams that no human practitioner can do at scale. The leverage is real: AI can generate a personalised sleep, nutrition, and movement protocol from continuous data faster and cheaper than any coach. The gap is compliance, not intelligence.

Crypto / DeSci — the data sovereignty layer. Patient-owned health records, consent encoded as smart contracts, research funding via token-coordinated data pools. The critical unsolved problem: who governs the longitudinal health record across a lifetime? Blockchain is the only credible candidate that doesn't require trusting a corporation that might be acquired or pivoted.

DePIN — the sensor network. Wearables as distributed health sensors earning for their data contributions. As device costs fall below $100 and sensor accuracy improves, the data collection problem approaches zero marginal cost.

Context​

  • Healthspan Industry — Full industry map
  • Performance — Friction map and disruption scoring
  • Platform — Technology infrastructure
  • Protocols — Care pathways and behaviour-change loops
  • Players — Who competes for the longitudinal health relationship
  • DeSci — Research coordination and data governance
  • DePIN — Sensor network infrastructure

Questions​

  • If biomarker data is the essential input and it's rapidly commoditising, where does the durable moat sit — in the protocol layer, the compliance engine, or the outcome data?
  • When does the compliance wall break? What is the intervention design that achieves 80%+ 6-month retention?
  • Who has the right to own a person's longitudinal health record — the person, the insurer, the EHR vendor, or a DeSci protocol?